Company: PTHS
Filing Date: 2025-08-13
Form Type: 10-Q
Source: 0001753926-25-001326
Chunk: 177

Company: Pelthos Therapeutics Inc.
Filing Date: 2025-08-13
Form: 10-Q
Item: Part I, Item 2
Chunk 177
---
949
    )

    (1,082,601
    ) 

    (25
    )%

37 

Operating
Expenses

Our
operating expenses consist of general and administrative expenses, research and development expenses and professional fees.

General
and Administrative Expenses

We
incurred general and administrative expenses for the six months ended June 30, 2025 and 2024 of $2,200,133 and $1,997,435, respectively.
For the six months ended June 30, 2025, compared to the same period in 2024, this represented an increase of $202,698, or 10%,
primarily as a result of increases of $138,396 in compensation expenses and an increase of $176,287 in stock compensation.

Research
and Development Expenses

We
incurred research and development expenses for the six months ended June 30, 2025 and 2024 of $709,112, and $479,561, respectively.
For the six months ended June 30, 2025, compared to the same period in 2024, this represented an increase of $229,551, or 48%,
with the details set forth in the table below:

    Six
    Months Ended June 30, 2025 and 2024

    2025

    2024

    $
    Change

    %
    Change

    Consultant
     
    $
    195,663

    $
    137,390

    $
    58,273

    42
    %

    Lab Gas

    1,062

    1,452

    (390
    )

    (27
    )%

    Lab Cell Storage

    31,223

    51,398

    (20,175
    )

    (39
    )%

    Chemistry Manufacturing
    and Controls (“CMC”)

    470,799

    169,617

    301,182

    178
    %

    IP Services

    10,365

    119,704

    (109,339
    )

    (91
    )%

    Total
     
    $
    709,112

    $
    479,561

    $
    229,551

    48
    %

The
Company incurred increased research and development expenses for the six months ended June 30, 2025